NASDAQ:MGEN Miragen Therapeutics (MGEN) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free MGEN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$17.14▼$18.0250-Day Range$14.34▼$23.0152-Week Range$4.66▼$34.05Volume707,739 shsAverage Volume134,027 shsMarket Capitalization$68.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Miragen Therapeutics alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Miragen Therapeutics Stock (NASDAQ:MGEN)Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.Read More Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. MGEN Stock News HeadlinesJanuary 30, 2024 | investing.comViridian Therapeutics Inc (VRDN)See More Headlines Receive MGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryN/A Current SymbolNASDAQ:MGEN CUSIPN/A CIK1590750 Webwww.signalgenetics.com Phone720-643-5200FaxN/AEmployees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($20.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,870,000.00 Net Margins-1,393.50% Pretax MarginN/A Return on Equity-141.66% Return on Assets-88.74% Debt Debt-to-Equity Ratio0.20 Current Ratio4.23 Quick Ratio4.23 Sales & Book Value Annual Sales$4.46 million Price / Sales15.22 Cash FlowN/A Price / Cash FlowN/A Book Value$6.78 per share Price / Book2.56Miscellaneous Outstanding Shares3,908,000Free FloatN/AMarket Cap$67.88 million OptionableNot Optionable Beta1.66 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Jason A. Leverone CPA (Age 46)CPA, CFO, Sec. & Treasurer Comp: $355kDr. William Stuart Marshall Ph.D. (Age 56)Co-Founder & Sr. Technical Advisor Comp: $521kDr. Diana Escolar (Age 58)Chief Medical Officer Comp: $484.38kMs. Lee M. Rauch (Age 65)CEO & Director Dr. Jonathan Violin Ph.D. (Age 45)Pres & COO Eric N. OlsonCo-Founder & Chairman of Scientific Advisory BoardDr. Michael R. Bristow (Age 75)Co-Founder & Member of the Scientific Advisory Board Dr. Marvin H. Caruthers (Age 80)Co-Founder & Scientific Advisory Board Member Mr. Vahe Bedian Ph.D.Chief Scientific OfficerDr. Aimee L. JacksonVP of ResearchMore ExecutivesKey CompetitorsEnzo BiochemNYSE:ENZPersonalisNASDAQ:PSNLAkuminNASDAQ:AKUMQExagenNASDAQ:XGNDermTechNASDAQ:DMTKView All Competitors MGEN Stock Analysis - Frequently Asked Questions How were Miragen Therapeutics' earnings last quarter? Miragen Therapeutics, Inc. (NASDAQ:MGEN) released its earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%. What other stocks do shareholders of Miragen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Novan (NOVN) and Aeterna Zentaris (AEZS). This page (NASDAQ:MGEN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.